New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL) ...Middle East

- Data from Phase 1/2 EPCORE™ NHL-1 study show patients treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates as presented at the 65th American Society of Hematology (ASH) congress - Follicular lymphoma is the second most common...

Hence then, the article about new data for bispecific antibody epcoritamab duobody cd3xcd20 shows strong durable treatment response for patients with difficult to treat relapsed refractory r r follicular lymphoma fl was published today ( Saturday 09/12/2023 - 08:05 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL) )

Also on site :

• Microsoft, Meta, and Google just announced billions more in AI spending. Only Google convinced investors it’s paying off
• 2026 Billboard Women in Music Red Carpet: The Best Photos
• Meta’s AI Is Delivering but Comes With a Hefty Price Tag .. PYMNTS.com